$QBIO NEW YORK, April 30, 2020 (GLOBE NEWSWIRE) --
Post# of 53495


Denis Corin, CEO of Q BioMed Inc., called back in to SmallCapVoice.com for a follow up interview to discuss the recent news and events for the Company. Early in the coronavirus saga, that would evolve into a global health pandemic, QBIO made a major announcement about the work being done along with its research partner Mannin Research Inc. The combined efforts of the two companies was to develop a potential adjunct treatment for various infectious diseases like the coronavirus. Recent news highlighted the urgency for the rapid development of novel drugs for the treatment of life-threatening complications caused by COVID-19 and other viral infections. Corin gives an update as well as an overall overview of QBIO’s work in this area.

